SMN2 and proximal spinal muscular atrophy: Nevertheless, concerns persist that treating SMA patients with nusinersen, which is delivered directly to the CSF to target LMNs, may alter disease trajectory and reveal novel pathologies caused by chronic SMN deficiency outside the CNS (Tizzano and Finkel, 2017).